Expand VTVT Menu
VTVT MENU

VTVT Stock Posts


VTVT stock declines -39.1% in after hours trading. See the latest news.

After Hours Decliner

VTVT VTV Therapeutics - Class A21.20+0.19+0.9%

After Hours:12.92-8.28 (-39.1%)

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Globe NewswireFri, 26-Jul 4:05 PM
VTVT stock increases 29.4% in premarket,

Premarket Gainer

VTVT VTV Therapeutics - Class A1.77+0.07+4.1%

Premarket:2.29+0.52 (+29.4%)

vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

Globe NewswireThu, 23-Sep 4:30 PM
VTVT stock increases 31.4% in premarket,

Premarket Gainer

VTVT VTV Therapeutics - Class A2.36-0.08-3.3%

Premarket:3.10+0.74 (+31.4%)

vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer

Globe NewswireTue, 22-Jun 7:30 AM
VTVT stock declines -34.0% in premarket,

Premarket Decliner

VTVT VTV Therapeutics - Class A2.970.000.0%

Premarket:1.96-1.01 (-34.0%)

vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes

Globe NewswireTue, 15-Dec 6:15 PM
VTVT stock increases 66.2% in premarket,

Premarket Gainer

VTVT VTV Therapeutics Cl A2.10+0.09+4.5%

Premarket:3.49+1.39 (+66.2%)

vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

Globe NewswireMon, 10-Feb 7:00 AM
VTVT stock increases 61.1% in premarket,

Premarket Gainer

VTVT VTV Therapeutics Cl A2.85-0.07-2.4%

Premarket:4.59+1.74 (+61.1%)

vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Business WireTue, 16-Oct 4:30 PM
Load Earlier Posts
Market Data Delayed 15 Minutes